Allo-ASC

Allogeneic adipose-derived mesenchymal stem cells · Seoul National University Hospital

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Allo-ASC, covering 2025-04-06 to 2025-04-06. Get the full timeline:

Most recent: Clinical Trial Update: Treatment of Intractable Common Extensor Tendon Injury Using Mesenchymal Stem Cells (Allo-ASC) [Phase 2]